Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Contraception Continuation”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 343 records · Page 19Linked to original sources
PubMed1992

Fibrinolytic activity in bleeding associated with intrauterine contraceptive devices.

A prospective study was conducted to assess endometrial fibrinolytic activity before and after insertion of copper 250 (Multiload) and after removal of the IUCD. Fibrinolytic activity was measured on the fibrin plate in the form of zone of lysis. Sixty two women in the control group had fibrinolytic activity of endometrium in the range of 0.3-9.5 cm2 (mean +/- SD 1.77 +/- 1.27), 40 women who wanted to have the IUCD removed, because of reasons other than bleeding had a range of 0-9.5 cm2 (mean +/- SD 2.28 +/- 1.88) while 48 women who had the IUCD removed because of subjective menorrhagia had a range of 2.24-7.56 cm2 (mean +/- SD 4.75 +/- 1.20) which was higher than in the other two groups.

Adult↗
PubMedDate not supplied

Premature discontinuation of contraception in Australia.

Life-history data from a nationally representative survey of Australian women were used to examine discontinuation of contraceptive methods because of accidental pregnancy, side effects or dissatisfaction. The pill was the most successfully used method, with a first-year discontinuation rate of 10% for all three reasons. Side effects dominated the reasons for the premature discontinuation of both the pill and the IUD, while the reasons for discontinuing the condom stemmed equally from pregnancy and dissatisfaction with the method. Discontinuation of the diaphragm resulted largely from accidental pregnancy. Hazards models were used to identify the correlates of discontinuation of each method. Predictors of premature discontinuation reflect the availability of methods, physiological reactions to them and the social characteristics of their users. Discontinuation of the pill because of side effects or dissatisfaction was more likely among poorly educated women, non-Protestants and recent users, and less likely among teenagers. Discontinuation of the IUD was related entirely to physiological factors: Nulliparous women and users of unmedicated devices were at a greater risk than other women of accidental pregnancy, and nulliparous women were at greater risk of discontinuation associated with side effects. Nulliparous women were also more likely to discontinue the condom because of pregnancy, as were non-Protestants and the Australian-born.

Adolescent↗
PubMed1991

The NORPLANT system of contraception.

The NORPLANT system is the first new methodology to be introduced in the past 30 years in the field of contraception. It is a subdermal, reversible system of Silastic capsules containing the synthetic progestin levonorgestrel. Advantages and disadvantages are discussed. Compliance-free use and high effectiveness are its main characteristics.

Female↗
PubMed1991

Adolescent women's contraceptive decision making.

A modified rational decision model incorporating salient events and social influences (particularly from sexual partners) is used to analyze adolescent women's consistent use of oral contraceptives (OCs) over a six-month period. Data are taken from a panel study of 308 clients of an inner-city family planning clinic. Expected OC use was computed for each subject on the basis of subjective expected utility (SEU) theory, and is found in multivariate analyses to be a significant predictor of actual OC use. In addition, variables representing baseline and follow-up partner influences, the salience of pregnancy for the subject, and positive side effects of OCs during the first months of use are found to predict OC use. Partner's support of OC use during follow-up and positive side effects of OCs are found to predict OC use among subjects for whom OC use was not the expected decision according to baseline SEU. Implications of the findings for models of adolescents' contraceptive behavior and for clinicians are discussed.

Adolescent↗
PubMed1991

Norplant implants: the mechanism of contraceptive action.

OBJECTIVE: To determine if fertilization occurs unnoticed among Norplant users who are ovulatory. DESIGN: Serial blood samples were obtained during 1 month from sexually active Norplant users experiencing regular menstrual bleeding patterns and a control group of noncontracepting women trying to conceive. The sequential blood samples were assayed for the presence of human chorionic gonadotropin (hCG). SETTING: All samples were obtained from women receiving contraceptive service and health care at the Center for Research and Services in Human Reproduction and Contraception, Santo Domingo, The Dominican Republic. Assays for hCG were performed at the Department of Biomedical Sciences, University of Tampere, Finland. PATIENTS, PARTICIPANTS: A total of 32 women using Norplant implants were enrolled in the treatment group, and 20 women of proven fertility who were attempting to conceive served as a control group. INTERVENTIONS: Duration of Norplant use was as follows: 4 in the 2nd year of use, 13 in the 3rd year, 11 in the 4th year, 3 in the 5th year, and 1 in the 7th year. MAIN OUTCOME MEASURE: The determination of pregnancy was based on the presence of hCG in the luteal phase, using a sensitive and specific immunoenzymatic assay that can detect dimeric hCG as early as 7 days after ovulation. RESULTS: Nine pregnancies were detected. All were in the control group trying to conceive. Six of these advanced to clinical pregnancies, and three did not proceed beyond the next expected menses. None of the Norplant users had evidence of hCG production, whether the observed cycles were anovulatory or ovulatory. The probability of finding no pregnancies in the ovulatory months at risk among Norplant users is between 1 in 50 and 1 in 150,000. The null hypothesis that Norplant users conceive at a natural rate can be rejected at the 0.05 level. CONCLUSION: Interruption of early pregnancy (menstrual abortion) does not play a role in the mechanism of action of Norplant contraceptive implants.

Chorionic Gonadotropin↗
PubMedDate not supplied

Oral contraceptive pill use after an initial visit to a family planning clinic.

A retrospective study of 1,311 women making initial family planning visits to metropolitan-area health department clinics found that many women switch methods or discontinue use in the first year following the clinic visits. Among a subgroup of women, most of whom selected the pill as their primary method and who used the pill for at least one of the months in the study period, almost half either changed methods or used no method at some point during a follow-up period averaging eight months. This includes 13 percent of women who made two or more changes. In addition, only 42 percent said they took a pill every day, and only half of these said they always took their pill at about the same time every day. Despite such irregularities, pill users were approximately one-third as likely to get pregnant during the study period as women making an initial family planning visit to a health department clinic who did not use the pill at all.

Contraception Behavior↗
PubMed1990

[Clinical experiences with femovan (Gynera)].

The low dose oral contraceptive Femovan/Gynera which contains 0.03 mg Ethinylestradiol and 0.075 mg Gestoden was examined in several clinical trials. Those trials proved its contraceptive effectiveness, its controlling influence on the menstrual cycle and a low incidence of unwanted side-effects. The data reported are based on the experience of more than 100,000 women representing nearly 600,000 treatment cycles. The results of all the different investigations compiled here underline a high contraceptive effectiveness and excellent control of the cycle when using the respective preparation. The rate of unwanted side-effects was low.

Adolescent↗
PubMed1990

Modern trends in contraception.

Substantial improvements have been made in oral contraceptives, a new injectable contraceptive (Norplant), and the intrauterine device (IUD). Major risks with oral contraceptives have declined substantially, and a number of noncontraceptive health benefits have been discovered. Norplant is probably the first new contraceptive in recent years, and offers long-term contraception with high efficacy and modest risks. The IUD, by carefully selecting users, is a safe and efficacious contraceptive method. The major risk, pelvic inflammatory disease (PID), is far less common if one avoids use in the presence of risk factors for PID.

Contraceptive Agents, Female↗
PubMedDate not supplied

Contraceptive failure in the United States: an update.

This report provides an update of the authors' previous estimates of first-year probabilities of contraceptive failure for all methods of contraception. Estimates are provided of failure during typical use (which includes both incorrect and inconsistent use) and during perfect use (correct use at every act of intercourse). The difference between these two probabilities provides a measure of how forgiving of imperfect use each method is. These revisions are prompted by recent studies that provide the first estimates of failure during perfect use for periodic abstinence and the cervical cap, by more complete evaluations of implants, and by the appearance of the Copper T 380A and disappearance of other IUDs from the US market. Also provided is a more complete explanation of how the previous estimate of the probability of becoming pregnant while relying solely on chance should be interpreted, and this estimate is revised slightly downward.

Clinical Trials as Topic↗
PubMedDate not supplied

Clinical evidence of the minimal androgenic activity of norgestimate.

The goal in improving the progestational component of oral contraceptives (OCs) is to enhance the selectivity of the progestin by achieving a high degree of contraceptive efficacy while decreasing undesirable side effects associated with existing progestational agents. The androgenic activity of current progestins results in changes in lipid metabolism, particularly decreased levels of high-density lipoprotein cholesterol (HDL), which have been associated with an increased risk of coronary heart disease (CHD). A progestin with high antiovulatory activity and minimal androgenicity would offer a clear therapeutic advantage in oral contraception. Norgestimate (NGM) is a new progestin with a unique profile of biological activity that has demonstrated a high level of selectivity in preclinical assays. The present studies were conducted to confirm clinically the low androgenic activity of NGM. Norgestimate (0.25 mg) in combination with 0.035 mg ethinyl estradiol (NGM 0.25/35) was compared with 0.30 mg norgestrel combined with 0.030 mg ethinyl estradiol (Lo/Ovral) in two multicenter clinical studies. In the first study (1,261 women), HDL levels were significantly increased from baseline levels in NGM 0.25/35 subjects but were significantly decreased in Lo/Ovral subjects. Increases in low-density lipoprotein cholesterol (LDL) levels were moderate in the NGM 0.25/35 group and pronounced in the Lo/Ovral group. A favorable lipid profile in NGM 0.25/35 subjects was also reflected in the LDL/HDL ratios, which were significantly lower in the NGM 0.25/35 subjects than in the Lo/Ovral subjects. Sex hormone binding globulin (SHBG) binds androgens, preventing clinical expression of androgenic activity. As a result, elevations in SHBG levels reduce bioactive (unbound) androgen levels and decrease the potential for androgenic side effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Acne Vulgaris↗
PubMedDate not supplied

Fertility reduction and the quality of family planning services.

The purpose of this paper is to determine whether a focus on quality of family planning services is consistent with meeting demographic objectives. An analytical framework that links the six elements of quality with fertility is described. A review of existing literature and analysis suggest that improvements in quality of family planning services by enhancing the choice of contraceptive methods available in a country would increase the overall practice of contraception and thus would result in fertility reduction.

Contraception↗
PubMed1988

Experience with the use of depo-medroxyprogesterone acetate in a Nigerian population.

Eight hundred and ten patients who accepted to use depo-medroxyprogesterone acetate (DMPA) for contraception were studied over a period of 11 years (1976-1986). Important side-effects observed were amenorrhoea (36.3%), weight gain (15.8%), weight loss (10.6%), metrorrhagia (6.7%) and menorrhagia (6.0%). Amenorrhoea, menorrhagia and metrorrhagia were major reasons for discontinuation of DMPA in 11% of acceptors. There were no cases of pregnancy, genital or breast malignancies during DMPA use. Our experience indicates that DMPA as a contraceptive is effective and should be available for suitable clients who demonstrate oestrogen intolerance.

Adult↗
PubMedDate not supplied

Management of the lost IUD.

Records of twenty-six patients who presented at the University College Hospital, Ibadan with 'lost' IUDs between 1 July 1980 and 30 April 1982 were analysed. During the 22-month study period there were 3476 IUD insertions. Routine evaluation showed that eighteen IUDs (69.2%) were intrauterine whilst eight IUDs (30.8%) were extrauterine. Seventeen (65.4%) intrauterine devices were recovered by routine D and C. Of the eight extrauterine devices, six (23.1%) were removed by laparoscopy, one (3.8%) was removed by laparotomy and one (3.8%) was removed by colpotomy. It is concluded that it is preferable for all extrauterine devices to be removed in order to discourage psychosomatic symptomatology commonly associated with forgotten devices.

Adult↗
PubMedDate not supplied

Contraceptive discontinuation among married women in the United States.

Using data from the 1982 National Survey of Family Growth (NSFG), this analysis reports differentials in contraceptive discontinuation among married women aged 15-44 years in the United States. The total discontinuation rate is broken down into change to no method (termination) or to a different method (a method switch), and rates are obtained for specific methods. In addition, sociodemographic differences in risks associated with each type of discontinuation are shown. Discontinuation rates are compared to use-failure rates to provide a more comprehensive understanding of the implications of discontinuation for contraceptive efficacy.

Actuarial Analysis↗